Biowaiver as a Bioequivalence Study Option [PDF]
SCIENTIFIC RELEVANCE. Biowaiver is a procedure for establishing the bioequivalence of generic and reference products without in vivo studies. Regulatory requirements for this procedure, as described in a variety of documents, differ in certain features ...
E. A. Volkova +3 more
doaj +5 more sources
Comparator product issues for biowaiver implementation: the case of Fluconazole [PDF]
The aim of this work was to assess if the commercially available Fluconazole drug products (Reference, Generic and Similar) would meet the biowaiver criteria from Food and Drug Administration (FDA) and Brazilian Agency for Health Surveillance (ANVISA ...
Raul Edison Luna Lazo +8 more
doaj +7 more sources
Utility of in vitro release testing (IVRT) to assess ‘sameness’ of 1% clotrimazole creams for use as a biowaiver [PDF]
The October 2022 draft United States Food and Drug Administration (FDA) guidance presents an option of in vitro release test (IVRT) studies as a biowaiver for topical drug products submitted in abbreviated new drug applications (ANDAs).
Hannah Wellington +3 more
doaj +3 more sources
Comparison of in vitro, in vivo, and in silico bioavailability results of different prednisone tablet formulations to assess the feasibility of possible biowaiver [PDF]
Introduction: The immediate-release solid oral products containing very soluble and permeable drugs are candidates for the biowaiver process. This work aims to compare in vitro, in silico, and in vivo data to establish if previously published prednisone
Leonardo Henrique Toehwé +7 more
doaj +5 more sources
Development and validation of a UV spectrophotometric method for biowaiver studies in pyrazinamide tablets [PDF]
Context: For regulatory reasons, a biowaiver is characterized as the substitution or exemption of bioavailability and/or bioequivalence research with in vitro dissolution tests, according to the Biopharmaceutical Classification System (BCS).
Vanessa Saldaña-Bobadilla +7 more
doaj +3 more sources
Biowaiver monographs for immediate-release solid oral dosage forms: Voriconazole [PDF]
According to the ICH M9 Guideline, the triazole antifungal voriconazole is a Biopharmaceutics Classification System (BCS) class II drug, being highly soluble at the highest dose strength but not at the highest single dose. Although the ICH M9 allows for consideration of BCS-based biowaivers in such cases, voriconazole does not meet the additional ...
Beran, Kristian +10 more
core +5 more sources
BIOWAIVER STUDY OF IMMEDIATE RELEASE GLIMEPIRIDE TABLETS [PDF]
Objective: Demonstrating therapeutic equivalency regarding the efficacy and safety among originator products and generics is a key step in permitting the marketing of generic products. The study aimed to evaluate the bioequivalence of five different generic brands of Glimepiride tablets under biowaiver conditions. Methods: The quality of the ...
SIHAM ABDOUN +5 more
core +5 more sources
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Empagliflozin [PDF]
Naseem A Charoo +2 more
exaly +4 more sources
Biowaiver monograph for immediate-release solid oral dosage forms: Amlodipine besylate. [PDF]
Amlodipine besylate is a calcium channel blocker widely used for treating hypertension and coronary artery disease. This biowaiver monograph evaluates the suitability of BCS-based biowaivers for immediate-release (IR) oral dosage forms containing ...
de la Cruz-Cruz P +13 more
europepmc +4 more sources
Biopharmaceutics classification system: importance and inclusion in biowaiver guidance [PDF]
Pharmacological therapy is essential in many diseases treatment and it is important that the medicine policy is intended to offering safe and effective treatment with affordable price to the population.
Lorena Barbosa Arrunátegui +4 more
doaj +3 more sources

